Key Highlights: Implications: Usema adds another early DCGI‑approved semaglutide brand to India’s GLP‑1 wave, giving USV a bioequivalent, locally manufactured injectable that fits neatly i...
Key Highlights: Implications: Obeda’s Day‑1 launch with DCGI approval and head‑to‑head Phase III data positions Dr. Reddy’s as a clinically credible, early GLP‑1 player, even at a higher ~...
Key Highlights: Implications: Zydus is differentiating in a crowded GLP‑1 space with a single reusable multi‑dose pen and 15 mg/3 mL cartridge, simplifying titration and potentia...
Key Highlights: Implications: By pricing its once‑weekly semaglutide at around ₹450 per week via a pre‑filled disposable pen, Alkem is positioning one of the lowest‑cost GLP‑1 op...
Key Highlights: Implications: By launching semaglutide under two differentiated brands with full dose coverage and price points 60%+ below innovator levels, Sun is set to rapidly expand ac...
Key Highlights: Implications: With Sundae vials starting at ₹1,290 per month and a pen device to follow, Eris is leveraging Natco’s low‑cost manufacturing while using its strong diab...
Key Highlights: Implications: By launching Day‑1 multi‑dose vials at ₹1,290–₹1,750 per month and claiming 70–90% discounts vs pens and innovator brands, Natco is setting the floor on...
